Vol 47, No 2 (2013)

open access

Page views 208
Article views/downloads 324
Get Citation

Connect on Social Media

Connect on Social Media

Evaluation of efficacy, safety and tolerability of fingolimod in patients with the relapsing form of multiple sclerosis – 12-month observation. A preliminary report

Zdzisław Maciejek1, Hanna Wójcik-Drączkowska2, Sławomir Wawrzyniak1, Anna Niezgodzińska-Maciejek1
DOI: 10.5114/ninp.2013.34719
Neurol Neurochir Pol 2013;47(2):145-151.


Background and purpose

Oral fingolimod 0.5 mg daily was approved in the European Union in 2011 for the treatment of relapsing multiple sclerosis in the aggressive form and as a second line treatment in patients with high disease activity despite interferon beta therapy. The aim of this study was the evaluation of efficacy, safety and tolerance of fingolimod in patients with relapsing-remitting multiple sclerosis (RRMS) during a 12-month observation period.

Material and methods

The investigated group consisted of 11 patients aged between 23 and 63 years. All patients underwent immunomodulatory treatment (disease modifying drugs – DMD) or immunomodulatory treatment in combination with mitoxantrone (Mx) without a positive effect for 3–5 years. Patients received oral fingolimod 0.5 mg daily during 12 months. Disability was evaluated with Kurtzke Expanded Disability Status Scale (EDSS) scale. Safety and tolerability of fingolimod were evaluated by adverse events monitoring, laboratory tests, and ophthalmological and skin assessment.


Before the initiation of fingolimod treatment all the patients progressed in disability and in MRI changes including five cases with gadolinium-enhancing lesions. During fingolimod treatment there was no new relapse in any patient and no patient stopped the treatment because of any adverse event. During the 12-month treatment, EDSS improvement was observed in seven patients, three patients were stable, and one patient progressed by 0.5 point in the EDSS.


In our study patients fingolimod was effective, safe and well tolerated independently of disease activity and previous treatment.

Article available in PDF format

View PDF Download PDF file

Neurologia i Neurochirurgia Polska